成都哪里有精索静脉曲张医院-【成都川蜀血管病医院】，成都川蜀血管病医院,成都治疗血管畸形费用要多少,成都小腿静脉{曲张}造影要多少钱,成都哪家医院治疗血管瘤好一点,成都肝血管瘤科医院哪家好,成都怎么治理脉管畸形,成都哪里治老烂腿的
成都哪里有精索静脉曲张医院成都血栓手术费用,成都做下肢静脉曲张手术的价格,成都精索静脉曲张科医院医院,成都在哪治疗海绵状血管瘤,成都治小腿血管炎的专业医院,成都中医怎么治疗好静脉血栓,成都治疗婴幼儿血管瘤手术需要多少钱
"China is one of our top-priority markets with product launches and potential growth," Saroukos said, adding that the company, which ranked 16th among multinational pharmaceutical companies in China, currently has a window of opportunity due to government healthcare reforms.
"China demonstrated its independent pursuit of mastering key technologies in large passenger aircraft manufacturing," he said. "It has also created valuable opportunities in global aviation."
"By serving such tech giants, Chinese chip companies have an unprecedented opportunity to grow into global players," Huang said, adding that the country now uses more than half of the world's semiconductors.
"But they didn't have any wounds so we got them back in the water."
"China first and the rest of the world next," Glaser said explaining the company's overall strategy. "The primary market for our new products is in China and then we will take it as a starting point to expand our businesses to other parts of the world."
